Loading clinical trials...
Loading clinical trials...
A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Conditions
Interventions
ARQ-252 cream 0.3%
ARQ-252 Vehicle cream
+2 more
Locations
5
United States
Arcutis Site 123
San Diego, California, United States
Arcutis Site 167
Coral Gables, Florida, United States
Arcutis Clinical Site 102
Rolling Meadows, Illinois, United States
Arcutis Site 162
Austin, Texas, United States
Arcutis Clinical Site 163
Pflugerville, Texas, United States
Start Date
March 4, 2021
Primary Completion Date
August 9, 2021
Completion Date
August 9, 2021
Last Updated
July 12, 2024
NCT07431177
NCT07352293
NCT07437560
NCT07398807
NCT07357870
NCT07267273
Lead Sponsor
Arcutis Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions